Aravax

Melbourne, Australia

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.

Jan 2024

Series B

Top Investors

Brandon CapitalUniseedNovartis Venture FundBreakthrough VictoriaTenmile

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Aravax's investors?

Aravax's investors include Brandon Capital, Uniseed, Novartis Venture Fund, Breakthrough Victoria, Tenmile.

Where is Aravax headquartered?

Aravax is headquartered in Melbourne, Australia.

What does Aravax do?

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.

What stage is Aravax at?

Aravax is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 23, 2024.

MLA

"Aravax — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/aravax. Accessed July 1, 2026.

APA

VCBacked. (2024). Aravax — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/aravax

Wikipedia (cite web)

{{cite web |title=Aravax — Funding & Investors |url=https://www.vcbacked.co/company/aravax |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 23, 2024.